IP Verse

Hamm & Wittkopp competitive analysis

Explore the latest publications and patents granted to Hamm & Wittkopp, showcasing their recent innovations and technological advancements.

Explore patent oppositions filed by Hamm & Wittkopp against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP3272738	Processes For Preparing Jak Inhibitors And Related Intermediate Compounds	INCYTE	Aug 12, 2025
EP4321157	New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)	NOVARTIS	Jul 23, 2025
EP3784283	Cannabidiol Preparations And Its Uses	GW RESEARCH	Jul 22, 2025
EP3226841	Anticancer Compositions	ARAGON PHARMACEUTICALS	Jul 7, 2025
EP4097091	Solid State Forms Of Mavacamten And Process For Preparation Thereof	ASSIA CHEMICAL INDUSTRIES	Jun 18, 2025
EP2818163	Composition For Nasal Application With Improved Stability	MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFT	Mar 20, 2025
EP4005555	Methods For Ensuring Resuspension Of Paliperidone Palmitate Formulations	JANSSEN PHARMACEUTICA	Feb 17, 2025
EP3773593	Treatment Of Hidradenitis Suppurativa Using Jak Inhibitors	INCYTE	Feb 14, 2025
EP3217983	Enhancement Of Tumor Response To Chemotherapy By Activation Of The Asmase/Ceramide Pathway Through Timed Administration Of A Short-Acting Anti-Angiogenic Agent	MEMORIAL SLOAN KETTERING CANCER CENTER	Jan 31, 2025
EP3090730	Novel Pharmaceutical Composition	NOVARTIS	Jan 10, 2025

Discover the latest PTAB cases involving Hamm & Wittkopp, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Hamm & Wittkopp with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced	Strategy Type
HAMM & WITTKOPP	57	-	-	-	Highly Aggressive
CELGENE	-	65	-	11	Non-Active
JANSSEN PHARMACEUTICA	1	54	-	1	Defensive
NOVARTIS	6	406	-	21	Defensive